Compare VFF & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VFF | DMAC |
|---|---|---|
| Founded | 1989 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.2M | 428.6M |
| IPO Year | N/A | N/A |
| Metric | VFF | DMAC |
|---|---|---|
| Price | $3.23 | $7.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | ★ 1.1M | 232.5K |
| Earning Date | 03-12-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $351,979,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.43 | N/A |
| P/E Ratio | $17.05 | ★ N/A |
| Revenue Growth | ★ 56.61 | N/A |
| 52 Week Low | $0.45 | $3.19 |
| 52 Week High | $4.99 | $10.42 |
| Indicator | VFF | DMAC |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 48.54 |
| Support Level | $2.98 | $7.47 |
| Resistance Level | $3.39 | $8.24 |
| Average True Range (ATR) | 0.16 | 0.57 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 43.33 | 42.14 |
Village Farms International Inc owns and operates intensive agricultural greenhouse facilities in British Columbia and Texas, where it produces, markets and sells tomatoes, bell peppers and cucumbers. Its wholly owned subsidiary, Pure Sunfarms, is a vertically integrated licensed producer and supplier of cannabis products sold to other licensed providers and provincial governments across Canada and internationally. The Company's wholly owned subsidiary, Balanced Health, develops and sells, cannabidiol (CBD) based products including ingestible, edible and topical applications. The operating segments of the Company are VF Fresh (Produce), Cannabis Canada, Cannabis U.S., Clean Energy, and Leli . The company makes majority of its revenue from the Produce segment.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.